Short Interest in Fresenius SE & Co. (OTCMKTS:FSNUY) Drops By 96.9%

Fresenius SE & Co. (OTCMKTS:FSNUY) was the recipient of a significant decrease in short interest during the month of August. As of August 31st, there was short interest totaling 32,056 shares, a decrease of 96.9% from the August 15th total of 1,029,832 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily volume of 141,927 shares, the short-interest ratio is presently 0.2 days.

Fresenius SE & Co. Stock Performance

Fresenius SE & Co. stock traded up $0.18 during mid-day trading on Friday, hitting $13.19. 19,563 shares of the company’s stock traded hands, compared to its average volume of 149,413. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.27 and a quick ratio of 0.98. The firm has a 50 day simple moving average of $12.92 and a two-hundred day simple moving average of $12.53. Fresenius SE & Co. has a fifty-two week low of $10.33 and a fifty-two week high of $33.93. The stock has a market cap of $29.71 billion, a price-to-earnings ratio of 16.69 and a beta of 0.62.

Fresenius SE & Co. (OTCMKTS:FSNUY) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). The company had revenue of $6.91 billion during the quarter, compared to analyst estimates of $6.65 billion. Fresenius SE & Co. had a net margin of 6.67% and a return on equity of 10.33%. On average, research analysts expect that Fresenius SE & Co. will post 1.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

FSNUY has been the topic of several recent analyst reports. Morgan Stanley reaffirmed an “overweight” rating on shares of Fresenius SE & Co. in a research report on Tuesday, July 21st. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Fresenius SE & Co. in a report on Thursday, August 6th. Three analysts have rated the stock with a Buy rating, According to MarketBeat.com, Fresenius SE & Co. presently has a consensus rating of “Buy”.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a Germany-based global health care company headquartered in Bad Homburg. The company develops and provides products and services for hospitals, outpatient care, and patients with chronic or complex medical conditions.

Its principal operating businesses are Fresenius Kabi and Fresenius Helios. Fresenius Kabi supplies medicines, clinical nutrition products, infusion and transfusion technologies, and related devices and services. Fresenius Helios operates hospitals and outpatient facilities, primarily in Germany and Spain, providing a broad range of medical and surgical care.

Fresenius traces its origins to a pharmacy established by the Fresenius family in Frankfurt in the 15th century and has evolved into an international health care group serving markets across Europe, North America, Latin America, Asia, and other regions.